Start Over

Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus.

Authors :: Chasset F
Jaume L
Mathian A
Abisror N
Dutheil A
Barbaud A
Kottler D
Girard C
Jousse-Joulin S
Tauber M
Livideanu CB
Avettand-Fenoel V
Lhote R
Pha M
Amoura Z
Source :: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2023 Jul; Vol. 89 (1), pp. 171-173. Date of Electronic Publication: 2023 Mar 05.
Publication Year :: 2023
Abstract: Competing Interests: Conflicts of interest Dr Chasset received grant/research support from AstraZeneca; participated in an advisory board related to lupus for AstraZeneca, GSK, Celgene, and Principabio; and received speaking fees and honoraria from AstraZeneca and GSK. Dr Mathian has received grant/research support from Sobi; participated in advisory board related to lupus for AstraZeneca; received payment for expert testimony for GSK; received support for attending meetings and/or travel from AstraZeneca and GSK; and received consulting fees, speaking fees, and honoraria from AstraZeneca, GSK, Otsuka, and Novartis. Dr Livideanu received speaking fee and honoraria from Blueprint Medicine, Lilly, and UCB and participated in advisory board for AbbVie, Boehringer Ingelheim, Blueprint Medicine, and UCB. Dr Avettand-Fenoel received grant/research support and speaking fees from Gilead and ViiV Healthcare. Dr Amoura has received grant/research support from GSK, AstraZeneca, Roche, Novartis, and Amgen; participated in advisory board related to lupus for GSK, AstraZeneca, Kezar, Amgen, and Otsuka; and received consulting fees, speaking fees, and honoraria from AstraZeneca and GSK. Drs Jaume, Abisror, Dutheil, Barbaud, Kottler, Girard, Jousse-Joulin, Tauber, Lhote, and Pha have no conflicts of interest to declare.